D2C ayurveda model Kapiva has launched a Rs 50 crore innovation fund to assist research-led product growth in Ayurveda.

Named the Kapiva Innovation Fund, the initiative is open for functions beginning immediately and can again tasks throughout the analysis lifecycle, from early tutorial work to programmes nearing commercialisation.

Eligible candidates embody analysis establishments, PhD students, clinicians, hospitals, laboratories, incubators and early-stage startups working in Ayurveda, plant-based therapeutics and integrative well being.

Kapiva stated cheque sizes will likely be round Rs 50 lakh for early-stage analysis, whereas late-stage programmes may entice investments starting from Rs 4 crore to Rs 6 crore.

Alongside capital, the corporate will provide entry to its in-house specialists, scientific infrastructure, regulatory steering and mentorship. It additionally plans to broaden its R&D facility in Bengaluru as a part of the initiative.

The fund will concentrate on areas resembling novel formulations, standardisation, phytochemistry, synthetic intelligence functions in Ayurveda, pre-clinical and scientific research, extraction applied sciences and bioactive enhancement. The corporate stated the target is to translate conventional ayurvedic data into outcomes which might be clinically examined and related to actual well being issues.

“For many years, Ayurveda has been seen as both faith-based or purely conventional knowledge. We consider its future lies in being outcome-led and evidence-backed. This fund is a long-term wager on that future,” co-founder Ameve Sharma stated.

Kapiva presently runs in-house R&D programmes and collaborates with establishments together with THSTI, Manipal Faculty of Pharmaceutical Sciences and Manipal Hospitals. The corporate follows structured testing protocols and conducts scientific trials on choose merchandise.

Based by Ameve Sharma and Shrey Badhani, Kapiva sells ayurvedic diet and wellness merchandise throughout classes resembling dietary supplements, gummies, capsules, juices, teas and skincare. It has a portfolio of over 100 merchandise and likewise provides consultations with ayurvedic docs. The corporate’s prime classes embody diabetes care, gymnasium and sports activities diet, vitality, and liver and coronary heart well being, with diabetes dietary supplements being its highest-selling section. Kapiva sells by its personal D2C web site, on-line marketplaces and offline retail shops.

The capital earmarked for the innovation fund has been drawn from Kapiva’s most up-to-date fundraise. The corporate has raised round $120 million so far, together with a $60 million Sequence D spherical in September 2025 led by 360 ONE Asset and Vertex Development.

Kapiva has stated it’s getting ready for an preliminary public providing and plans to go public within the subsequent two to a few years.